Figure 3
Maximum potential β1 activation vs age. The percentage expression of β1 after treatment with 8A2 activating antibody declined with increasing age in a subset of 24 AML patients (Spearman R = −0.83, P < .001).
Maximum potential β1 activation vs age. The percentage expression of β1 after treatment with 8A2 activating antibody declined with increasing age in a subset of 24 AML patients (Spearman R = −0.83, P < .001).
